drugset / Trial / NCT00794703

A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections

NCT00794703

Phase 3 Completed 288 enrolled Astellas Pharma Inc
RandomizedParallel-groupOpen-labelPrevention

Summary

The objective of this study is to compare the efficacy and safety between Mycamine and Itraconazole oral solution in preventing invasive fungal infections on autologous(malignant blood diseases) or allogeneic hematopoietic stem cell transplant patients

Timeline

Start
2008-11
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Itraconazole Small molecule 5 mg/kg Oral
Subject Micafungin Peptide 50 mg Intravenous